Merit Medical Systems Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Merit Medical Systems Stock Forecast and Price Target
The average price target of $88.00 for Merit Medical Systems's stock set by distinguished analysts in recent weeks would represent a potential upside of approximately 19.27% from the last closing price in April, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $112.00 and a low estimate of $85.00. If you are interested in MMSI stock, it is important to also consider its competitors.
19.27% Upside
Merit Medical Systems Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Merit Medical Systems's Price has seen a drop from $45.97 to $0.00 – a 100.00% decrease. For next year, analysts predict Fair Value of $89.99, which would mean an increase of 100.00%. Over the next eight years, experts predict that Merit Medical Systems's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.14 | Buy/Sell | $174.55 | 16.33% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.53 | Buy/Sell | $118.92 | 17.64% |
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$335.61 | Buy/Sell | $353.16 | 9.20% |
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$73.17 | Buy/Sell | $70.14 | 12.07% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.74 | Buy/Sell | $92.47 | 19.76% |
Merit Medical Systems Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Merit Medical Systems's Revenue has grown by 30.45%, rising from $963.88M to $1.26B. For next year, analysts predict Revenue of $1.32B, which would mean an increase of 5.36%. Over the next ten years, experts predict that Merit Medical Systems's Revenue will grow at a rate of 20.40%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$231.55 | Buy/Sell | $284.47 | 19.84% |
| EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$86.43 | Buy/Sell | $91.18 | 12.23% |
| CAH Stock Forecast | Cardinal Health Inc | Hold |
13
|
$103.21 | Buy/Sell | $108.07 | 10.94% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4543 Stock Forecast | Terumo | Outperform |
18
|
¥5.63k | Buy/Sell | ¥4.97k | -9.46% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.13 | Buy/Sell | $44.86 | 12.14% |
| PHIA Stock Forecast | Koninklijke Philips N.V. | Hold |
18
|
19.75€ | Buy/Sell | 19.42€ | -1.27% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.98 | Buy/Sell | $81.06 | 10.56% |
| ABMD Stock Forecast | Abiomed | - |
16
|
$377.79 | Buy/Sell | $380.00 | -88.33% |
| 7733 Stock Forecast | Olympus | Outperform |
18
|
¥2.17k | Buy/Sell | ¥2.30k | 10.37% |
Merit Medical Systems EBITDA Forecast for 2023 - 2025 - 2030
Merit Medical Systems's EBITDA has seen impressive growth In the last three years, rising from $141.29M to $217.45M – a growth of 53.90%. In the next year, analysts believe that EBITDA will reach $290.33M – an increase of 33.52%. For the next eight years, the forecast is for EBITDA to grow by 61.70%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SWAV Stock Forecast | Shockwave Medical | Hold |
4
|
$330.00 | Buy/Sell | $239.91 | 1.52% |
| TFX Stock Forecast | Teleflex Inc | Hold |
13
|
$206.71 | Buy/Sell | $263.46 | 28.20% |
| PEN Stock Forecast | Penumbra | Outperform |
9
|
$204.41 | Buy/Sell | $258.62 | 40.43% |
Merit Medical Systems EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Merit Medical Systems's EBIT has grown by 169.95%, rising from $47.22M to $127.47M. For the next year, analysts predict that EBIT will reach $254.21M – an increase of 99.43%. Over the next nine years, experts believe that Merit Medical Systems's EBIT will grow at a rate of 168.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GETI B Stock Forecast | Getinge AB | Outperform |
18
|
kr235.10 | Buy/Sell | kr226.10 | -3.02% |
| HAE Stock Forecast | Haemonetics | Outperform |
16
|
$90.99 | Buy/Sell | $70.17 | 15.40% |
| ITGR Stock Forecast | Integer Holdings | Outperform |
16
|
$109.58 | Buy/Sell | $95.00 | 18.63% |
Merit Medical Systems EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Merit Medical Systems's EPS has seen a drop from $1.65 to $0.00 – a 100.00% decrease. For next year, analysts predict EPS of $3.23, which would mean an increase of 100.00%. Over the next eight years, experts predict that Merit Medical Systems's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NARI Stock Forecast | Inari Medical | Outperform |
14
|
$38.42 | Buy/Sell | $82.67 | 82.20% |
| IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$28.34 | Buy/Sell | $46.60 | 53.49% |
| LMAT Stock Forecast | LeMaitre Vascular | Outperform |
18
|
$65.46 | Buy/Sell | $59.86 | 6.94% |
Site Navigation
.jpg)